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Biomarkers May Predict Unfavorable Neurological
Outcome after Mild Traumatic Brain Injury
Lawrence M. Lewis,1 Linda Papa,2 Jeffrey J. Bazarian,3 Art Weber,4 Rob Howard,5 and Robert D. Welch6

Abstract

The objective of this study was to determine if initial or repeat measurements of serum concentrations of glial fibrillary acidic
protein (GFAP) or ubiquitin C-terminal hydrolase L1 (UCH-L1) are predictive of an acute unfavorable neurological outcome
in patients who present to the emergency department (ED) with brain injury and an initial Glasgow Coma Scale Score (GCS)
of 14–15. This multi-center observational trial included brain-injured adults presenting to the ED, receiving a head computed
tomography (CT) and venipuncture for biomarker concentration measurements within 6 h of injury. Subjects had repeat
serum sampling and GCS scores every 4 h for the first 24 h, if available for assessment. We analyzed blood samples using an
enzyme-linked immunosorbent assay approved by the Food and Drug Administration (FDA). Wilcoxin two-sample test was
used to compare initial and repeat serum concentrations for both biomarkers between CT-positive patients who did not have
an acute unfavorable neurological outcome and those patients who did. A total of 145 enrolled subjects had adequate data for
analysis; 69 were CT-positive, 74 were CT-negative, and 2 were CT-inconclusive. Five subjects developed an acute
unfavorable neurological outcome, defined as need for intracranial pressure monitoring, craniotomy, persistent neurological
deficits, or death resulting from brain injury. Initial median serum concentrations of GFAP and UCH-L1 (obtained <6 h from
injury) were significantly greater in CT-positive patients who had an acute unfavorable neurological outcome than in CTpositive patients who did not (GFAP: 5237 pg/mL [IQR 4511, 8180] versus 283.5 pg/mL [IQR 107, 1123]; p = 0.026; UCHL1: 3329 pg/mL [QR 1423, 5010] versus 679.5 pg/mL [IQR 363, 1100] p = 0.014). Repeat serum testing (6- < 12 h from
injury) showed that UCH-L1 serum concentration, but not GFAP, was also significantly greater in the acute unfavorable
neurological outcome group than in those without an unfavorable outcome: 1088 pg/mL versus 374 pg/mL; p = 0.041.
Keywords: biomarkers; mild traumatic brain injury; neurological deterioration

Introduction

B

rain injury is a common reason for seeking care in an
emergency department (ED), with *2,900,000 traumatic
brain injury (TBI) related ED visits in 2014.1 The vast majority of
these injuries are considered mild traumatic brain injury (mTBI),
defined as a Glasgow Coma Scale score (GCS) of 13–15 inclusive.2
Clinical decision guidelines have been developed to identify patients with mTBI at low risk for intracranial injury who could
forego head computed tomography (CT).3–6 Investigators have also
tried to identify factors that would help predict risk for neurological
deterioration in CT-positive patients with mTBI.7–11 However,
there is currently no validated clinical decision tool to safely and
effectively risk stratify these patients.11
Over the past decade, neuro-biomarkers have been shown to be
useful in predicting the need for a head CT in ED patients with

mTBI.12–15 Research evaluating the utility of neuro-biomarkers to
predict risk of acute neurological deterioration after mTBI is
scarce. The primary objective of this investigation was to determine
if initial or serial measurements of serum concentrations of glial
fibrillary acidic protein (GFAP) or ubiquitin C-terminal hydrolase
L1 (UCH-L1) could differentiate between patients with mild TBI
(GCS >13) who developed an acute unfavorable neurological
outcome (defined by the need for intracranial pressure monitoring,
craniotomy, persistent neurological deficits, or death as a result of
brain injury) and those CT-positive patients who did not.
Methods
Participants
This was an unplanned sub-analysis of a larger multi-center
study entitled ‘‘A Prospective Evaluation of UCH-L1 and GFAP
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BIOMARKERS MAY PREDICT UNFAVORABLE OUTCOME AFTER MTBI
Biomarker Kinetics After Mild Brain Injury Trauma’’ (VIGILANT
Clinical Trial NCT02541123). Approval by the local institutional
review board and by the ethics board of the United States Army
Medical Research and Material Command (USAMRMC) Office of
Research Protections (ORP) Human Research Protection Office
(HRPO) Department of Defense was obtained at each study site.
We followed the Strengthening The Reporting of Observational
Studies in Epidemiology (STROBE) guidelines for reporting of
observational studies.16
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previous reports have demonstrated that this is inherently a higher
risk group, and most clinical guidelines suggest closely observing
these patients.11,17 All subjects had blood obtained for repeat biomarker concentration measurements every 4 h for up to 24 hours
from the initial blood draw, if they were available to the research
assistant. Repeat GCS and neurological assessments were performed with each blood draw by research assistants trained in their
administration, using a written scorecard.
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Imaging
Inclusion criteria
The parent study included patients 18–95 years of age, presenting to the ED within 6 h of sustaining a non-penetrating brain
injury with an initial GCS score of 13–15. It began as a nonconsecutive sample of brain-injured subjects, initially enrolling
only those patients who were CT-positive. After enrolling 51
subjects, the protocol was amended to enroll subjects prior to their
CT result, including CT-negative and CT-positive subjects. The
parent study also included 40 uninjured control subjects.
Our sub-analysis included those subjects with a documented
brain injury, a GCS >13 on presentation, capable of informed
consent, who received a head CT and had blood obtained for serum
analysis within 6 h of injury (Fig. 1). We excluded the five subjects
with a GCS of 13 who were enrolled in the parent study, because

All CTs were ordered by the treating physicians based on their
clinical judgement. Treatment was predicated on the real-time CT
reading at the individual institutions. A neuroimaging review
committee (NRC) consisting of three independent neuroradiologists reviewed all CTs. CT results reported in this study are based
on the adjudication readings of the NRC (Fig. 1, flow diagram).
Biomarker collection, processing, and measurement
The initial blood sample for biomarker analysis was obtained
within 6 h of brain injury in all patients, and the repeat sample was
obtained between 6 and 12 h of brain injury. The elapsed time
between the reported time of brain injury and the time of blood
collection for biomarker analysis defines ‘‘time from injury’’ for

FIG. 1. This subject enrollment flow diagram includes all the subjects enrolled into the parent VIGILANT trial. The sub-analysis we
performed begins with the 149 brain-injured subjects who were evaluated. Because we analyzed and reported our results based on the
computed tomography (CT) interpretation, the two CT-inconclusive subjects were not included in the bottom row. Neither of these
subjects showed any neurological deterioration.
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our statistical analyses. Blood samples (5 mL) were collected and
processed to serum within 30 min of collection, frozen at -80C,
and shipped on dry ice to a central laboratory for analysis. Samples
were analyzed using the Food and Drug Administration (FDA approved Banyan BTI (Brain Trauma Indicator) test for GFAP and
UCH-L1, a sandwich enzyme-linked immunosorbent assay. The
reportable range for GFAP using this assay is 10–320 pg/mL. The
range for UCH-L1 is 80–2560 pg/mL. Samples with initial biomarker concentrations at the upper limit of the reportable range
were diluted and re-analyzed to determine the actual serum concentration. The lower limit of quantification for this assay is
10 pg/mL for GFAP and 80 pg/mL for UCH-L1. For both assays,
the intra- and inter-run coefficient of variation was <10%. Laboratory personnel performing these measurements were blinded to
clinical data.
Data analysis
Our primary analysis compared initial and repeat median serum
concentration of GFAP and UCH-L1 between patients with an
initial GCS of 14 or 15 and an acute intracranial injury on their
initial head CT, who developed an acute unfavorable neurological
outcome and those that did not, using a Wilcoxon two-sample test
for pairwise comparisons.
We performed a secondary analysis using a Kruskal–Wallis test
to independently compare the GFAP and UCH-L1 serum concentrations at two time points (< 6 h and 6- < 12 h from injury) across
three clinical groups: CT-positive patients who were stable or improved at all assessments, CT-positive patients who had a transient
decrease in their neurological status at one or more assessments but
did not have an unfavorable outcome, and those (all CT-positive)
who had an acute unfavorable neurological outcome.
As this was an exploratory analysis, there were no adjustments
for multiple comparisons and as it was a secondary analysis of
previously acquired data, we did not perform a power analysis to
determine enrollment. We used SAS version 9.4 for analyses.
Results
Of 156 brain-injured subjects enrolled in the parent study, 149
were included in the current analysis (Fig. 1). Seventy (47.6%) had
an acute injury on head CT, 77 (51.7%) had no acute injury, and two
CTs (1.3%) were inconclusive, as determined by the NRC. The two
subjects with inconclusive CT results were excluded from analysis,
reducing the study population to 147. Of these 147 subjects, 143
(97%) had an initial serum biomarker concentration and at least two
neurological and GCS assessments recorded within the first 24 h,
and therefore were analyzable for a change in GCS score or neurological deterioration (Fig. 1).
Subject characteristics
Table 1 describes demographic and clinical characteristics for
our patient population, stratified by neurological outcome and CT
result. Most subjects (n = 123) were neurologically stable or improved over the course of the first 24 h after enrollment, and remained that way the duration of their study participation. Seventeen
subjects (12 CT-positive) had a transient decrease in their GCS
score at some point in the first 24 h following enrollment, but did
not develop an acute unfavorable neurological outcome.
Five subjects (all CT-positive) developed an acute unfavorable
neurological outcome. Table 2 provides details of the specific CT
lesions in the subjects with an acute unfavorable neurological
outcome, along with their initial biomarker concentrations and
eventual outcome.

LEWIS ET AL.
Biomarker analysis
Among subjects with an acute intracranial injury on their initial
CT scan, initial median serum concentrations for both GFAP and
UCH-L1 were significantly greater in those who developed an
acute unfavorable neurological outcome than in those who did not:
5237 pg/mL (interquartile range [IQR] 4511, 8180) versus
284 pg/mL (IQR 107, 1123); p = 0.026 and 3329 pg/mL (IQR 1423,
5010) versus 680 pg/mL (IQR 363, 1100); p = 0.014 respectively
(Table 3). Figures 2A and 2B demonstrate median serum biomarker
concentrations for those patients who developed an acute unfavorable neurological outcome and those who did not, along with the
entire spread of data, for both the initial and repeat serum samples.
Median serum concentration of UCH-L1 decreased on repeat
measurements across all groups and time points except one, but was
still significantly greater at the 6-< 12 h time period in those patients
with an acute unfavorable neurological outcome than in those
without; 1088 pg/mL versus 374 pg/mL; ( p = 0.041). At the 6-<
12 h post-injury time frame, GFAP no longer showed a significant
difference between those patients with an unfavorable outcome and
CT-positive patients without an unfavorable outcome (Table 3).
CT-positive subjects with a transient decrease in their GCS score
were found to have a median serum GFAP concentration, which
was midway between that of CT-positive subjects who were stable/improved and that of those with an acute unfavorable outcome
(Table 1). This was not the case for UCH-L1.
Discussion
Clinical decision rules for obtaining a head CT in adults with
mTBI have good sensitivity for detecting patients with intracranial
lesions that require neurosurgical intervention.17 This high sensitivity is in large part because the vast majority of patients who meet
guideline criteria for not requiring a head CT will not have an acute
intracranial lesion. However, in the subpopulation of patients with
mTBI and an acute intracranial lesion, our study and others show
that the need for neurosurgical intervention is not trivial, ranging
between 3.5% and 8.8%, despite the initial low risk.10,11
Intensive care unit (ICU) admission practices for patients with
mTBI and an acute intracranial injury on head CT vary widely.18
Over-utilization of the ICU for these patients increases healthcare
costs and can lead to decreased ICU bed availability, delays in
admitting other critically sick or injured patients, and subsequent ED crowding. Under-use of the ICU may lead to worse
outcomes because of undetected or delayed recognition of clinical
deterioration.
A recent systematic review and meta-analysis of patients with
mTBI (GCS of 13–15), and a positive head CT showed a pooled
prevalence of clinical deterioration of 11.7%, and a pooled estimate
of neurosurgical intervention risk of 3.5%.11 This is somewhat
lower than the 8.8% neurosurgical intervention found in a large
multi-year query of the National Trauma Databank.10 Univariate
analyses across most studies showed increasing age, a lower initial
GCS,specific injury patterns on CT, and anticoagulation to be
significant risk factors for deterioration.
Heterogeneity in populations and definitions, confounding variables, and conflicting results among studies precluded pooling of
study populations for the construction of a model that could reliably
identify a population at very low risk for deterioration.11
We found that brain-injured patients who present to an ED with
an initial GCS score of 14 or 15 and a negative initial head CT
rarely deteriorate to the point of requiring neurosurgical intervention (we had none). However, in our study, patients with a positive
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56 (17, 250)
69
488 (186, 853)

69
4.32 (1.147)

65
9.21 (1.251)

52
680 (376, 1077)

50
4.43 (1.006)

50
9.11 (1.311)

4 (5.8%)
65 (94.2%)

9 (17.3%)
43 (82.7%)

52
281 (111, 941)

20 (29.0%)
46 (66.7%)

10 (19.2%)
41 (78.8%)

4 (5.8%)
59 (85.5%)
6 (8.7%)

4 (5.8%)
65 (94.2%)

1 (1.9%)
51 (98.1%)

15 (28.8%)
36 (69.2%)
1 (1.9%)

51 (73.9%)
18 (26.1%)

69
43.8 (20.2)

32 (61.5%)
20 (38.5%)

52
55.9 (18.2)

CT positive (n = 52) CT negative (n = 69)

All (n = 17)

15
9.04 (1.002)

17
4.58 (0.998)

17
534 (322, 1740)

17
266 (214, 1584)

5 (29.4%)
11 (64.7%)
1 (5.9%)

3 (17.6%)
14 (82.4%)

1 (5.9%)
16 (94.1%)

0
16 (94.1%)

11 (64.7%)
6 (35.3%)

17
58.4 (20.9)

11
8.80 (0.704)

12
4.58 (0.834)

12
496 (319, 1575)

12
965 (168, 1771)

4 (33.3%)
7 (58.3%)
1 (8.3%)

3 (25.0%)
9 (75.0%)

1 (8.3%)
11 (91.7%)

0
11 (91.7%)

8 (66.7%)
4 (33.3%)

12
58.9 (22.3)

4
9.72 (1.488)

5
4.58 (1.439)

5
799 (337, 3059)

5
222 (214, 259)

1 (20.0%)
4 (80.0%)
0

0
5 (100.0%)

0
5 (100.0%)

0
5 (100.0%)

3 (60.0%)
2 (40.0%)

5
57.0 (19.5)

5
7.61 (0.447)

5
3.55 (0.335)

5
3329 (1423, 5010)

5
5237 (4511, 8180)

0
5 (100.0%)
0

3 (60.0%)
2 (40.0%)

2 (40.0%)
3 (60.0%)

0
5 (100.0%)

2 (40.0%)
3 (60.0%)

5
52.6 (20.4)

Unfavorable neurological
outcomec
CT positive (n = 12) CT negative (n = 5)
CT positive (n = 5)

Transient neurological dysfunctionb

b

This group includes 123 patients, but two had inconclusive CT results and were excluded from further analysis, leaving a total of 121.
Includes 17 subjects that had a 1 point or greater decrease in GCS score at some point in their course, but who did not develop an unfavorable neurological outcome.
c
Unfavorable neurological outcome is defined as requiring emergency neurosurgery, persistent neurological deficits, or death resulting from a brain injury.
d
A subject is counted, at most, once per time from injury category. If a subject has more than one blood draw in the given visit window category, then the result closest to the midpoint value is summarized. If a
subject has two results equidistant from the midpoint, then the result prior to the midpoint value is summarized.
CT, computed tomography; SD, standard deviation; GCS, Glasgow Coma Score; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase L1.

a

Age (years)
n
123
Mean (SD)
48.9 (20.3)
Sex
Male
84 (68.3%)
Female
39 (31.7%)
Ethnicity
Hispanic or Latino
5 (4.1%)
Not Hispanic or Latino
118 (95.9%)
Race
Black or African American
30 (24.4%)
White
89 (72.4%)
GCS at Initial Visit
14
13 (10.6%)
15
110 (89.4%)
Loss of consciousness
No
19 (15.4%)
Yes
97 (78.9%)
Unknown
7 (5.7%)
GFAP (pg/mL) at initial visit
n
123
Median (Q1,Q3)
164 (36, 445)
UCH-L1 (pg/mL) at initial visit
n
123
Median (Q1,Q3)
599 (257, 966)
Time from injury to initial
blood draw (in hours)d
n
121
Mean (SD)
4.36 (1.079)
Time from injury to repeat
blood draw (in hours)d
n
117
Mean (SD)
9.15 (1.273)

All (n = 123)

Stable/Improvinga

Table 1. Demographic and Clinical Characteristics by Clinical Category and Initial CT Result

Downloaded by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE St. Louis E-PACKAGE from www.liebertpub.com at 01/17/21. For personal use only.

2628

LEWIS ET AL.
Table 2. CT Results, Biomarker Concentrations, and Clinical Outcomes among Subjects with an Acute
Unfavorable Neurological Outcome

Subject ID
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121-008
124-003
124-021
124-037
127-003b

GFAPa (pg/mL) UCH-L1a (pg/mL)

Age

CT result

47
68
20
70
58

SDH/SAH / parenchymal hematoma ?EDH
SAH
Bifrontal hemorrhagic contusions, SDH
SDH / Parenchymal hematoma
Bilateral hematoma/acute on chronic with midline shift

8180/4050
5237/1216
4511/5317
11536/9110
47/25

3329/1088
1423/688
5594/3879
5010/3113
612/277

Outcome
Craniotomy / Death
Craniotomy
Craniotomy
Vegetative / Death
Death

a

The first value is the initial concentration (within 6 h of brain injury) and the second value is from a repeat serum sample 4 h after the initial sample.
Subject 127-003 had a significant previous brain injury.
CT, computed tomography; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase L1; SDH, subdural hematoma; SAH,
subarachnoid hematoma;
EDH, epidural hematoma.
b

initial head CT and a GCS score ‡ 14 had a 7.1% risk of an acute
unfavorable neurological outcome resulting in a neurosurgical intervention, a persistent neurologic deficit, or death.
The literature suggests certain criteria are predictive of adverse
outcomes, most notably the injury pattern on CT, particularly

swelling and midline shift. Clinical decision rules and specific head
CT criteria to reduce the number of patients with mTBI admitted to
an ICU have been previously developed.7–10,19–21 Nishijima and
coworkers found that four variables predicted need for ICU admission: GCS <15, non-isolated brain injury, age >65 years, and

Table 3. Initial and Repeat Serum GFAP and UCH-L1 Concentration in CT-Positive Subjects with and without
an Acute Unfavorable Neurological Outcome

Parameter

Time from injury category

GFAP (pg/mL)

0-<6 h
n
Mean (SD)
Median
Q1, Q3
Min, Max
p valuec
6-<12 h
n
Mean (SD)
Median
Q1, Q3
Min, Max
p valuec
0-<6 h
n
Mean (SD)
Median
Q1, Q3
Min, Max
p valuec
6-<12 h
n
Mean (SD)
Median
Q1, Q3
Min, Max
p valuec

UCH-L1 (pg/mL)

Stable/improving or transient
neurological dysfunctiona (n = 64)

Unfavorable neurological
outcomeb (n = 5)

62
963.2 (1520.5)
283.5
107.0, 1123.0
8, 7580

5
5902.2 (4289.2)
5237.0
4511.0, 8180.0
47, 11536
0.0259[3]

61
1282.1 (2008.8)
513.0
134.0, 1700.0
17, 11986

5
3943.6 (3584.1)
4050.0
1216.0, 5317.0
25, 9110
0.1173[3]

62
1009.63 (1032.931)
679.50
363.00, 1100.0
63.0, 5068.0

5
3193.60 (2172.513)
3329.00
1423.00, 5010.0
612.0, 5594.0
0.0143[3]

61
531.25 (424.105)
374.00
210.00, 703.0
63.0, 1869.0

5
1809.00 (1589.719)
1088.00
688.00, 3113.0
277.0, 3879.0
0.0411c

A subject is counted, at most, once per time from injury category. If a subject had more than one blood draw in the given visit window category, then
the result closest to the midpoint value is summarized. If a subject had two results equidistant from the midpoint, then the result prior to the midpoint
value is summarized.
a
Subjects were defined as having transient neurological dysfunction if they had a one or more-point decrease in GCS score or a transient neurological
deficit but did not go on to have an unfavorable neurological outcome.
b
Unfavorable neurological outcome is defined as requiring emergency neurosurgery, persistent neurological deficits, or death resulting from a brain
injury.
c
p value is from a Wilcoxon two-sample test and compares pairwise those patients with an acute abnormality on their initial head CT scan who are
stable/improving or had transient neurological dysfunction with those patients with an acute unfavorable neurological outcome.
CT, computed tomography; SD, standard deviation; GCS, Glasgow Coma Score; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal
hydrolase L1.
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Box Plot of Initial And Repeat GFAP Serum Concentration (pg/ml) In CT-Positive Patients
With And Without An Unfavorable Neurologic Outcome

A
12000

GFAP Serum Concentration (pg/ml)

10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
0 - <6

6 - <12
Time from Injury (hours)

Cohort

n:
Mean:
Median:

Stable/Improving + T ransient Neurologic Dysfunction

Unfavorable Neurologic Outcome

130
743
248

5
5902
5237

136
546
178

5
3944
4050

Box Plot of Initial And Repeat UCH-L1 Serum Concentration (pg/ml) In CT-Positive Patients
With And Without An Unfavorable Neurologic Outcome

B
6000
5500
UCH-L1 Serum Concentration (pg/ml)
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11000

5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
0 - <6

6 - <12
Time from Injury (hours)

Cohort

n:
Mean:
Median:

136
905
603

Stable/Improving + T ransient Neurologic Dysfunction

5
3194
3329

Unfavorable Neurologic Outcome

130
467
308

5
1809
1088

FIG. 2. (A) Transient neurological dysfunction includes subjects that had a transient 1 or more-point decrease in their Glasgow Coma
Scale (GCS) score but did not die or require surgery. Unfavorable neurological outcome is defined as requiring emergency neurosurgery,
having persistent neurological deficits, or death as a result of a brain injury. Initial serum concentration measurements were within 6 hours
of injury, repeat measurements were within 12 h of injury. Upper and lower bound of each box indicates the 75th and 25th percentiles,
respectively (i.e., the interquartile range [IQR]). In each box, the square marker symbol and horizontal line indicate the mean and median,
respectively. Median values at consecutive time points are connected by a line. (B) Transient neurological dysfunction includes subjects
that had a transient 1 or more-point decrease in their GCS score but did not die or require surgery. Unfavorable neurological outcome is
defined as requiring emergency neurosurgery, having persistent neurological deficits, or death as a result of a brain injury. Initial serum
concentration measurements were within 6 h of injury, repeat measurements were within 12 h of injury. Upper and lower bound of each box
indicates the 75th and 25th percentile, respectively (i.e, the IQR). In each box, the square marker symbol and horizontal line indicate the
mean and median, respectively. Median values at consecutive time points are connected by a line. Color image is available online.
swelling or shift on initial CT.9 The CT lesions seen in our five
patients who had an acute unfavorable neurological outcome varied, with only one showing significant midline shift (Table 2).
Although certain demographic, clinical, and imaging characteristics are useful in risk stratifying patients with mTBI for delayed
adverse neurological outcomes, the use of biomarkers may add
additional useful information. We are unaware of any previous

studies evaluating the potential utility of serum biomarkers to
stratify patients, with or without an acute injury on head CT, for risk
of acute neurological deterioration.
In this small study, initial serum concentrations of GFAP and
UCH-L1, obtained within 6 h of brain injury, were statistically
greater in patients who went on to have an acute unfavorable
neurological outcome than in those who did not. The repeat testing
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was less clear. Median serum UCH-L1 concentrations decreased in
all groups on repeat testing during the time window of 6–12 h. This is
consistent with previous studies.22,23 Median GFAP concentration
modestly increased on repeat testing in all groups except those with an
unfavorable outcome. The decrease in GFAP concentration on repeat
testing in those patients who had an unfavorable outcome seems
counterintuitive, and it should be noted that the IQR is large and the
number of subjects small. Papa and coworkers looked at the kinetics
of GFAP and UCH-L1 in TBI patients and demonstrated that UCHL1 concentration peaks early and decreases rapidly in patients with
acute intracranial lesions, whereas GFAP increases after 4 h to peak
near 16 h, before slowly declining.22 Welch and coworkers evaluated
the kinetics of GFAP and UCH-L1 in patients with mTBI and found
that GFAP, but not UCH-L1, increased modestly over time in patients
with an acute intracranial lesion compared with those without.23 This
effect peaked at *6 h post-injury and remained constant out to 24 h.
The number of subjects requiring neurosurgical intervention were
small in both of these studies. Larger studies are needed to further
clarify the kinetics of GFAP and UCH-L1 in patients who deteriorate
to the point of requiring neurosurgical intervention.
Finally, we noted a potential confounding factor that may warrant further investigation. Although four of the five subjects with
acute unfavorable neurological outcomes had initial GFAP concentrations >5000 pg/mL, one had an initial serum concentration
<100 pg/mL (Table 2). There was also an outlier with a very low
initial serum GFAP concentration in the cohort with a transient
decrease in GCS score. Both subjects had a history of a significant
previous brain injury. A recent article evaluating autoimmunity
after ischemic stroke and brain injury reported increased concentration of autoantibodies to S100 calcium-binding protein B
(S100B) in subjects with repetitive head trauma.24
These have been reported with GFAP as well and could interfere
with the immunoassay, leading to falsely low serum concentration
measurements.25
There are several limitations to this study. Most importantly, the
results are in a very small population (neurological deterioration
n = 5). There were several outliers, including the two subjects with a
previous brain injury mentioned previously. In a small study, having
a few outliers may significantly affect the results. Additionally, although the five patients with an acute unfavorable neurological
outcome had hard end-points, it is not clear what, if any, clinical
significance can be placed on a transient unexplained decrease in the
GCS score. Another limitation was the fact that although GCS
scores were obtained and recorded by trained personnel, the same
person may not have obtained consecutive GCS scores on any given
patient, increasing the possibility of measurement variability. The
inclusion criteria did not require that physicians utilize one of the
validated clinical decision rules for obtaining a head CT, but rather
allowed this to be decided by clinical judgement. We do not know
how often various clinical decision rules were utilized for determining the need for head CT. Finally, many patients did not have
biomarker samples at each time point, including some who did not
have a 6–12-h sample, further reducing the number of subjects for
analysis. A significantly larger study is needed to better evaluate
whether these biomarkers (or others) could play an important role in
helping predict which brain-injured patients with mTBI may be at
increased risk for clinical deterioration.
Conclusion
In this small exploratory study, initial median serum concentrations of GFAP and UCH-L1 (obtained <6 h from injury) were
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significantly greater in CT-positive patients who had an acute unfavorable neurological outcome than in CT-positive patients who
did not. Repeated measurement of UCH-L1 (at 6-< 12 h postinjury) but not GFAP also differentiated between these two groups.
Further study is required to verify these findings.
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